 |
Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab |
|---|---|
| Trade Name | Hepex-B |
| Orphan Indication | For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2003-07-15 00:00:00 |
| Sponsor | Cubist Pharmaceuticals;65 Hayden Avenue;Lexington, Massachusetts, 02421 |
